Current stock page

Financial Data

VRNA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Sep 6, 2026

VRNA

Financial Data
Verona Pharma plc
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 2/10
Low Priority
Relative Laggard
Score data as of Sep 6, 2026
Last price
Latest market quote
Momentum
Value34
Quality47
Risk Resilience54
Sentiment
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 6, 2026.

Income statement
8 periods
Metric2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30
Revenue$75.14M$59.03M$29.28M$4.21M$0$0$0$0
Gross Profit$71.68M$56.39M$27.65M$3.8M$0$0$0$0
Operating Income
Net Income$8.69M-$12.63M-$27.02M-$32.13M-$56.04M-$20.44M-$11.09M-$12.04M
EPS$0.1-$0.15-$0.33-$0.39-$0.69-$0.25-$0.14-$0.15
Cash flow statement
8 periods
Metric2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30
Operating Cash Flow$30.56M-$11.56M-$28.84M-$62.65M-$16.76M-$13.97M-$10.42M-$12.73M
Capital Expenditure$0$0-$535K-$9.62K-$29.02K-$15.99K$0$0
Free Cash Flow$30.56M-$11.56M-$29.37M-$62.66M-$16.78M-$13.98M-$10.42M-$12.73M
Net Cash Provided By Operating Activities$30.56M-$11.56M-$28.84M-$62.65M-$16.76M-$13.97M-$10.42M-$12.73M
Balance sheet
8 periods
Metric2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30
Total Assets$572.87M$525.94M$474.24M$381.82M$434.12M$289.91M$308.12M$292.47M
Total Debt$244.37M$2.13M$122.7M$224.33M$218.53M$41.19M$51.33M$20.3M
Cash And Cash Equivalents
Total Liabilities$294.6M$299.34M$269.68M$251.33M$265.85M$64.92M$58.84M$28.94M
Total Stockholders Equity$278.27M$226.6M$204.56M$130.49M$168.27M$224.99M$249.28M$263.53M
Key financial metrics
8 periods
Metric2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30
P/E ratio233.16-106.71-32.99-18.24-5.57-15.84-30.21-27.01
P/B ratio29.1123.817.4317.977.425.765.374.93
P/S ratio107.891.35121.77557.370000
Debt To Equity0.880.010.61.721.30.180.210.08
Free Cash Flow Yield
Financial ratios
8 periods
Metric2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30
P/E ratio
P/B ratio29.1123.817.4317.977.425.765.374.93
P/S ratio107.891.35121.77557.370000
Return On Equity3.12%-5.57%-13.21%-24.63%-33.30%-9.09%-4.45%-4.57%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
-2,155.44
multipleSep 5, 2026
Pb
32.9
multipleSep 5, 2026
Revenue Growth Yoy
27.3
percentSep 5, 2026
EPS Growth Yoy
166.84
percentSep 5, 2026
Gross Margin
95.45
percentSep 5, 2026
Operating Margin
1.27
percentSep 5, 2026
ROE
-1.56
percentSep 5, 2026
ROIC
0.31
percentSep 5, 2026
Debt To Equity
0.88
ratioSep 5, 2026
FCF Yield
0.03
percentSep 5, 2026
Technical indicators
Close
106.91
priceOct 6, 2025
Volume
1,871,959
volumeOct 6, 2025
Rsi14
indexOct 6, 2025
MACD
indexOct 6, 2025
MACD Signal
indexOct 6, 2025
MACD Histogram
indexOct 6, 2025
Adx14
indexOct 6, 2025
Sma50
priceOct 6, 2025
Sma200
priceOct 6, 2025
Atr14
priceOct 6, 2025
Historical Volatility
1.77
percentOct 6, 2025
Volume Ma20
volumeOct 6, 2025
Risk measures
Resilience Score
54
score_0_100Sep 5, 2026
Beta
0.05
ratioSep 5, 2026
Volatility Annual
2.18
percentSep 5, 2026
Max Drawdown
-0.39
percentSep 5, 2026
Sharpe Ratio
2.4
ratioSep 5, 2026
Var95
-0.2
percentSep 5, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

VRNA Financial Data FAQ

What is Verona Pharma plc's revenue?

Verona Pharma plc's revenue is one of the core financial data points for VRNA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Verona Pharma plc's revenue growing?

Revenue growth shows whether Verona Pharma plc is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is VRNA's EPS?

VRNA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Verona Pharma plc's net income?

Verona Pharma plc's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Verona Pharma plc generate?

Free cash flow shows how much cash Verona Pharma plc generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Verona Pharma plc have?

Cash and debt help frame VRNA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.